N@N

Market Maker Surveillance Report. TIVO, PFE, BSX, JNJ, CIM, UDRL, Bullishly Biased Price Friction For Tuesday, September 25th

^{Published on 2012-09-25 18:00:17 - WOPRAI}
 

September 25, 2012 / M2 PRESSWIRE / BUYINS.NET / www.buyins.net, announced today its proprietary Market Maker Friction Factor Report for Tuesday. Since October 2008 market makers are now required to be on the bid as much as they are on the offer and for like amounts of stock. This Fair Market Making Requirement is designed to prevent market makers from manipulating stock prices. On Tuesday there were 3723 companies with "abnormal" market making, 1739 companies with positive Friction Factors and 4112 companies with negative Friction Factors. Here is a list of the top companies with Abnormal Price Friction (bullish bias) in their stock prices. This means that there was more selling than buying in the stocks and their stock prices rose. TiVo Inc (NASDAQ:TIVO), Pfizer Inc (NYSE:PFE), Boston Scientific Corp (NYSE:BSX), Johnson & Johnson (NYSE:JNJ), Chimera Investment Corp (NYSE:CIM), Union Drilling Inc (NASDAQ:UDRL). To access Friction Factor, Naked Short Data and SqueezeTrigger Prices on all stocks please visit http://www.buyins.net .

Market Maker Friction Factor is shown in the chart below:

  Symbol  Change    Percent   Buy Volume   Buy %%    Sell Volume  Sell %%   Net Volume   Friction
  TIVO    $0.230    2.31%     3,542,466    43.74%    4,520,996    55.82%    -978,530     Abnormal
  PFE     $0.170    0.69%     9,206,396    27.24%    11,656,225   34.49%    -2,449,829   Abnormal
  BSX     $0.020    0.35%     5,721,084    30.90%    7,271,043    39.27%    -1,549,959   Abnormal
  JNJ     $0.320    0.46%     3,010,761    26.38%    4,203,840    36.84%    -1,193,079   Abnormal
  CIM     $0.070    2.57%     7,557,217    24.62%    14,411,046   46.96%    -6,853,829   Abnormal
  UDRL    $0.350    5.71%     2,850,201    35.56%    5,165,089    64.44%    -2,314,888   Abnormal

For example, the chart above shows TIVO with 978,530 greater shares of selling than buying (NetVol) and the stock price was up $0.23000. This means the Market Makers were trading the stock in a way inconsistent with normal supply and demand (Economics 101); more selling than buying should cause prices to drop.

TiVo Inc (NASDAQ:TIVO) - TiVo Inc., together with its subsidiaries, provides television technology and services that include digital video recorders (DVRs) in the United States and internationally. The company offers subscription-based TiVo service, which enhances home entertainment by providing consumers with a way to record, watch, and control live television, as well as enables to receive movies and television shows from cable, broadcast, and broadband sources in one interface. It also provides a platform for advertising and audience research measurement services. TiVo Inc. distributes the TiVo DVR through consumer electronics retailers and its online store at TiVo.com, as well as through distribution agreements with television service providers, such as satellite television providers, and international cable and broadcasting companies. As of January 31, 2010, it had approximately 1.5 million subscriptions to the TiVo service. The company was founded in 1997 and is headquartered in Alviso, California..

Pfizer Inc (NYSE:PFE) - Pfizer Inc., a biopharmaceutical company, offers prescription medicines for humans and animals worldwide. The company's Biopharmaceutical segments provides Lipitor for elevated LDL-cholesterol levels in the blood; Enbrel for rheumatoid arthritis, polyarticular juvenile rheumatoid arthritis, psoriatic arthritis, plaque psoriasis, and ankylosing spondylitis; Lyrica for post-herpetic neuralgia, diabetic peripheral neuropathy, fibromyalgia, neuropathic pain, adjunctive treatment of epilepsy, and general anxiety disorder, as well as for use as an adjunctive therapy for adult patients with partial onset seizures; Prevnar/Prevenar for invasive pneumococcal disease; Celebrex for osteoarthritis and rheumatoid arthritis, and acute pain; Viagra for erectile dysfunction; Xalabrands for reducing elevated eye pressure; Effexor XR for depressive, generalized anxiety, social anxiety, and panic disorders; and Norvasc for hypertension. It also offers Zyvox for gram-positive pathogens; Premarin for menopausal symptoms; Sutent for renal cell carcinoma; Geodon/Zeldox for schizophrenia; Detrol/Detrol LA for overactive bladder; Zosyn/Tazocin, an intravenous antibiotic; Genotropin for growth hormone deficiency; Vfend, an antifungal agent; and Protonix for gastroesophageal reflux disease; Chantix/Champix for aid smoking cessation; BeneFIX, ReFacto AF, and Xyntha for lifelong bleeding disorder; Caduet for cardiovascular events; Revatio for pulmonary arterial hypertension; Pristiq for depressive disorder; Aricept for Alzheimers disease; and Spiriva for breathing problems. The companys Diversified segment offers animal health products, such as vaccines, anti-infectives, anti-inflammatories, antiemetics, and parasiticides; consumer healthcare products, such as dietary supplements, pain management, respiratory, and personal care; nutrition products; and gelatin, liquid, softgel, non-animal, and fish gelatin capsules. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York..

Boston Scientific Corp (NYSE:BSX) - Boston Scientific Corporation develops, manufactures, and markets medical devices used in various interventional medical specialties worldwide. It offers cardiac rhythm management products, which monitor the heart and deliver electricity to treat cardiac abnormalities; and RF generators, intracardiac ultrasound and steerable ablation catheters, and diagnostic catheters for the diagnosis and treatment of cardiac arrhythmias. The company also provides interventional cardiology products, such as coronary stent systems, coronary revascularization products to treat patients with atherosclerosis and intraluminal catheter-directed ultrasound imaging catheters and systems; vascular access products, balloon catheters, stents and peripheral vascular catheters, wires, and accessories, as well as products for peripheral embolization procedures; and biliary stents, drainage catheters, and micro-puncture sets to treat, diagnose, and ease various forms of benign and malignant tumors. In addition, it offers coated and uncoated detachable coils, micro-delivery stents, micro-guidewires, micro-catheters, guiding catheters, and embolics to neuro-interventional radiologists and neurosurgeons to treat diseases of the neurovascular system; and endoscopy and interventional bronchoscopy products to diagnose and treat various digestive diseases, as well as pulmonary disease systems within the airway and lungs. Further, the company provides urology/womens health products to treat patients with urinary stone disease, benign prostatic hyperplasia, stress urinary incontinence, pelvic organ prolapse, and excessive uterine bleeding; and spinal cord stimulation system for the management of chronic intractable pain of the trunk and/or limbs. Boston Scientific Corporation markets its products through direct sales force, and a network of distributors and dealers. The company was founded in 1979 and is headquartered in Natick, Massachusetts with additional offices in Tokyo, Japan and Paris, France..

Johnson & Johnson (NYSE:JNJ) - Johnson & Johnson engages in the research and development, manufacture, and sale of various products in the health care field worldwide. The company operates in three segments: Consumer, Pharmaceutical, and Medical Devices and Diagnostics. The Consumer segment provides products used in baby care, skin care, oral care, wound care, and womens health care fields, as well as nutritional, over-the-counter pharmaceutical products, and wellness and prevention platforms under the names JOHNSONS, AVEENO, CLEAN & CLEAR, JOHNSONS Adult, NEUTROGENA, RoC, LUBRIDERM, Dabao, Vendome, LISTERINE, REACH, BAND-AID, PURELL, CAREFREE, STAYFREE, SPLENDA, TYLENOL, SUDAFED, ZYRTEC, MOTRIN IB, and PEPCID AC. The Pharmaceutical segment offers products in various therapeutic areas, such as anti-infective, antipsychotic, cardiovascular, contraceptive, dermatology, gastrointestinal, immunology, neurology, oncology, urology, and virology. Its products include REMICADE, a biologic approved for the treatment of immune mediated inflammatory diseases; PROCRIT, a biotechnology-derived product that stimulates red blood cell production; LEVAQUIN, which is used in the anti-infective field; RISPERDAL CONSTA, a injectable for the treatment of schizophrenia; CONCERTA, a product for the treatment of attention deficit hyperactivity disorder; ACIPHEX/PARIET, a proton pump inhibitor; DURAGESIC/Fentanyl Transdermal, a treatment for chronic pain; VELCADE for the treatment of multiple myeloma; PREZISTA for treating HIV/AIDS patients; and INVEGA, a atypical antipsychotic. The Medical Devices and Diagnostics segment primarily offers circulatory disease management products; orthopaedic joint reconstruction, spinal care, and sports medicine products; surgical care, aesthetics, and womens health products; blood glucose monitoring and insulin delivery products; professional diagnostic products; and disposable contact lenses. The company was founded in 1886 and is based in New Brunswick, New Jersey..

Chimera Investment Corp (NYSE:CIM) - Chimera Investment Corporation, a real estate investment trust, invests in residential mortgage backed securities (RMBS), residential mortgage loans, real estate-related securities, asset backed securities (ABS), and various other asset classes in the United States. It invests in agency and non-agency RMBS; whole mortgage loans comprising prime, jumbo prime, and Alt-A mortgage loans; and ABS, including debt and equity tranches of CDOs, consumer and non-consumer ABS, and commercial mortgage backed securities. The company has elected to be treated as a REIT for federal income tax purposes and would not be subject to income tax, if it distributes at least 90% of its REIT taxable income to its share holders. Chimera Investment Corporation was incorporated in 2007 and is based in New York, New York..

Union Drilling Inc (NASDAQ:UDRL) - Union Drilling, Inc. provides contract land drilling services and equipment primarily to independent natural gas producers in the United States. The company offers drilling rigs, as well as the drilling crews and ancillary equipment to operate its drilling rigs. The company provides drilling services to customers primarily engaged in developing unconventional natural gas formations. It has principal operations in the Appalachian Basin; the Arkoma Basin in eastern Oklahoma and Arkansas; and the Fort Worth Basin in northern Texas. As of December 31, 2009, it owned and operated a fleet of 71 land drilling rigs. The company was founded in 1997 and is based in Fort Worth, Texas..

About BUYINS.NET

BUYINS.NET, www.buyins.net , monitors trading in all US stocks in real time and maintains massive databases of short sale and naked short sale time and sales data, short squeeze SqueezeTrigger prices, market maker price movements, shareholder data, statistical data on earnings, sector correlation, seasonality, hedge fund trading strategies, comparable valuations. Reports include:

REGULATORY & COMPLIANCE NEWS

Friction Factor -- market maker surveillance system tracking Level II market makers in all stocks to determine Price Friction and compliance with new "Fair Market Making Requirements"

RegSHO Naked Shorts -- tracks EVERY failure to deliver in all US stocks and tracks all Threshold Security Lists daily for which stocks have naked shorts that are not in compliance with Regulation SHO

INVESTMENTS & TRADING

SqueezeTrigger -- 29 billion cell database tracks EVERY short sale (not just total short interest) in all US stocks and calculates volume weighted price that a short squeeze will begin in each stock.

Earnings Edge -- predicts probability, price move and length of move before and after all US stock earnings reports.

Seasonality -- predicts probability, price move and length of move based on exact time of year for all US stocks.

Group Trader -- tracks sector rotation and stock correlation to its sector and predicts future moves in ALL sectors and industry groups.

Pattern Scan -- automates tracking of every technical pattern and predicts time and size of move in all stocks.

GATS (Global Automated Trading System) -- tracks all known trading strategies and qualifies and quantifies which are working best in real time.

DISCLAIMER:

BUYINS.NET is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. BUYINS.NET has not been compensated by any of the above mentioned companies. Past performance is not indicative of future results. Please visit our web site, www.buyins.net , for complete risks and disclosures.

Contact:

BUYINS.NET Thomas Ronk 800-715-9999 tom@buyins.net www.buyins.net